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Abstract
Inflammatory myofibroblastic tumors (IMT) of the lung, first reported in 1939, are considered a subset of inflammatory pseudo
-tumors. They are a distinctive lesions composed of myofibroblastic spindle cells accompanied by an inflammatory infiltrate of pla-
sma cells, lymphocytes, and eosinophils. IMTs may be benign, invade surrounding structures, undergo malignant transformation, 
recur or may even metastasize. They can occur due to a genetic mutation or can occur secondary to infectious or autoimmune 
diseases. Patients may be asymptomatic, or present with cough, hemoptysis, dyspnea, pleuritic pain, constitutional symptoms 
or pneumonia. In this article we review the pathophysiology, genetics, clinical presentation, imaging findings of IMT of the lung. 
We also discuss the various surgical and non-surgical treatment options and the prognosis associated with this disease. 
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Adv Respir Med. 2018; 86: 27–35
Introduction
Inflammatory pseudo-tumors (IPT) were first 
described in 1905, in the orbital tissues of four 
patients, with infiltration of the soft tissue with 
lymphocytes [1]. They were labeled as ‘pseudo
-tumors’ because they clinically and radiologi-
cally mimicked malignancies [2]. Inflammatory 
myofibroblastic tumors (IMT) of the lung, first 
reported in 1939 [3], are considered a subset of 
these IPTs. They are a distinctive lesions compo-
sed of myofibroblastic spindle cells accompanied 
by an inflammatory infiltrate of plasma cells, 
lymphocytes, and eosinophils [4].
IMTs account for 0.04 to 0.1% of all pulmo-
nary neoplasms [5, 6]. They are more common 
in children and are the most common pediatric 
primary lung lesion [7, 8]. IMTs are usually benign 
and resection achieves complete cure. However, 
there are times when they invade surrounding 
structures, undergo malignant transformation, 
recur [9, 10] or may even metastasize [11, 12].
IMTs have been synonymously referred to 
as pseudo-sarcomatous myo-fibroblastic or fibro-
myxoid lesion, plasma cell granuloma, fibrous 
xanthoma, plasma cell pseudosarcoma, lymphoid 
hamartoma, myxoid hamartoma, omental mesen-
teric myxoid hamartoma, inflammatory myofi-
brohistiocytic proliferation, benign myofibrobla-
stoma, and inflammatory fibrosarcoma [4, 9, 13].
Pathophysiology and genetics
The exact pathophysiology and mechanism 
of neoplasia in IMTs is unknown. Several genes 
and chromosomal abnormalities have been found 
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to be associated with IMTs. Anaplastic Lymphoma 
Kinase (ALK) gene locus on 2p23 encodes a clas-
sical receptor tyrosine kinase (RTK) in mice and 
humans. An ALK rearrangement is discovered 
in approximately 40–50% of IMTs [14–17], but 
more commonly in younger population [18]. 
ALK rearrangements produce fusion proteins that 
constitutively activate tyrosine kinase, similar 
to its action in anaplastic large-cell lymphoma, 
diffuse large-cell lymphoma and non-small cell 
lung cancer (NSCLC) [18, 19]. As will be descri-
bed later, the ALK-RTK can be a target for newer 
drug therapies.
ROS-1 is a receptor tyrosine kinase (RTK) of 
the insulin receptor family. Chromosomal rearran-
gements involving the ROS-1 gene, on chromosome 
6q22, were originally described in glioblastomas as 
well as non-small cell lung cancers (NSCLC) [20]. 
Some IMTs without ALK rearrangement (ALK-ne-
gative) demonstrate ROS-1 gene fusions. One study 
reported that 4/9 (44%) of ALK-negative tumors had 
distinct ROS1 fusions [21]. There have been some 
rare cases of IMT that have been negative for ALK 
and ROS-1 mutations [22].
A subset of IMT lack ALK oncogenic acti-
vation but contain rearrangements targeting the 
HMGIC (also known as HMGA2) gene on chromo-
some 12q15. Chromosomal aberrations involving 
this region are very frequent among other benign 
tumors, such as lipomas, uterine leiomyomas, or 
pulmonary chondroid hamartoma [23]. There has 
been a significant association between transloca-
tions in IMT and a high rate of aneuploidy [24], 
the presence of which correlates well with local 
recurrence and more aggressive biologic behavior 
[13]. The presence of hyperdiploidy serves as an 
indicator of the neoplastic nature of IMTs. Deri-
vative of Chromosome (Der9) was reported in one 
case of an omental-mesenteric IPT [25]. It was an 
extra chromosome that evolved from a transloca-
tion between the long arm of chromosome 2 and 
the short arm of chromosome 9 [(2; 9) (q1, 3; p2, 
2)]. Other mutations such as PDGFR-b fusion have 
also been reported in some IMTs [21].
Association with other diseases
Multiple infections including pulmonary 
tuberculosis, pseudomonas lung infection, mo-
raxella catarrhalis, actinomycetes, mycoplasma, 
mycobacteria, Epstein-Barr virus and human 
herpes virus 8 (HHV-8) have also been reported 
with IPTs [10, 26–40].
Patients with autoimmune conditions such as 
Sjörgen’s syndrome have also been reported to have 
lung IMTs [41] and IPTs in choroid plexus [42], 
liver [43] and pancreas [44]. In one patient with 
lung IMT, concurrent B-cell lymphoma was seen 
[9]. IgG4 syndrome [45, 46] has been reported with 
IPTs; these tumors have been seen to form a sub-
set of this syndrome. Pulmonary and extra-pul-
monary IMTs have also been reported following 
hematopoietic stem cell [47–49], graft versus host 
disease [50] and solid-organ transplant [51–54].
Classification
The classification of IMTs is listed in Table 1. 
Clinical features
They may be asymptomatic, or present with 
cough, hemoptysis, dyspnea and pleuritic pain 
[5, 56]. Systemic symptoms such as fever, weight 
loss, malaise and fatigue can be seen in 15–30% 
of patients. Some may present with recurrent 
pneumonias [57, 58]. 
Imaging
Pulmonary IMTs occur more frequently in the 
lower lobes with a predilection for peripheral lung 
parenchyma and sub-pleural locations [7, 59]. 
On chest radiographs, pulmonary IMTs appear 
as solitary, circumscribed, lobulated lesions pre-
ferentially localized to the lower lobes, occasio-
nally with pleural effusions (Fig. 1) [56]. When 
IMT presents as a solitary pulmonary nodule, the 
main radiologic differential diagnosis includes 
a primary or secondary neoplasm, hamartoma, 
hemangioma, chondroma, and pulmonary sequ-
estration [60, 61].
On computed tomographic (CT) scans, in-
flammatory pseudotumors have a variable and 
nonspecific appearance, but most commonly 
they appear with heterogeneous attenuation 
and enhancement (Fig. 2A–C). On T1-weighted 
magnetic resonance (MR) images, these tumors 
have intermediate signal intensity and high 
signal intensity on T2-weighted images [60]. 
Calcification within the lesion occurs more 
frequently in children than in adults (Fig. 2A, B). 
The pattern of calcification can range from an 
amorphous, mixed, or fine fleck-like pattern to 
heavy mineralization. 
IMTs can be discovered bilaterally, with 
endobronchial lesions causing atelectasis and 
in the pulmonary arteries [60, 62–64]. IMTs may 
show uptake of fluorodeoxyglucose; and it may be 
used to monitor response to therapy [62, 65, 66]. 
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Table 1. Classification of IMT’s 
(A) Earliest classification by Cerfolio et al. [5]
Non-invasive IPT Invasive IPT
Asymptomatic patients Younger patient with systemic symptoms of fever, fatigue, or weight loss
Small lesions that do not invade surrounding 
structures
It is large and may invade local mediastinal structures or the chest wall
Grossly, it is an invasive tumor that grows through tissue planes
Pathologically, it is characterized by nuclear atypia and a high number of mitotic figures
Usually easily removed by wedge resection Usually requires a lobectomy or pneumonectomy for complete removal and may also 
require a concomitant chest wall resection
(B) Classification by Matsubara et al. [55]
Organizing pneumonia Fibrous histiocytoma Lymphoplasmacytic
Intra-alveolar lymphohistiocytic inflammation 
converting peripherally to intra-alveolar fibro-
sis and centrally to interstitial fibrosis (becau-
se of fibroblasts proliferation)
Predominant spindle cell proliferation, histio-
cytes in a storiform pattern and loss of the 
alveolar architecture
Predominant lymphocytes and plasma 
cells with little fibrosis
(C) 3 basic variants of IMT [4] as per WHO classification of soft tissue tumors
Resembling nodular fasciitis Resembling fibrous histiocytoma or fibroma-
tosis
Resembling scar or desmoid tumor
Loosely organized myofibroblasts in an 
edematous myxoid background with plasma 
cells, lymphocytes, eosinophils, and blood 
vessels
Dense aggregates of spindle cells arrayed in 
a variable myxoid and collagenized backgro-
und admixed with a distinctive inflammatory 
infiltrate, diffuse clusters of plasma cells, and 
lymphoid nodules
Collagen sheets with scattered plasma 
cells and eosinophils
Figure 1. Chest X-ray showing well circumscribed right lower lobe 
lesion
Interestingly, a positive uptake in 111 In-Diethy-
lene triamine pentaacetic acid (DTPA)-D-Phe1 
scan (Octreoscan) has been described implying 
response to somatostatin analogue receptors [67].
Associated serum biochemistry  
and histopathology
Laboratory evaluation may reveal microcytic 
anemia; increase in acute phase reactants such as 
erythrocyte sedimentation rate (ESR) and C-reac-
tive protein (CRP); thrombocytosis and polyclonal 
hypergammaglobulinemia. These findings have 
been attributed to overproduction of interleukin 
(IL)-6 [39, 57, 68].
On biopsy, the predominant cells seen are 
spindle cells. They are seen as interlacing fa-
scicles among a polymorphous inflammatory 
infiltrate consisting of mature plasma cells and 
small lymphocytes [10, 12]. Spindle cell prolifera-
tion is noted to be more marked in IMT, whereas 
lymphoplasmacytic infiltration is more prominent 
in IPTs [69]. An example of histopathology slides 
including immunohistochemistry from a patient 
with IMT is demonstrated in the attached figures 
(Fig. 3, 4A, B, 5–7]. On immunohistochemistry 
(IHC), virtually all IMTs show reactivity for 
vimentin. The reactivity for smooth muscle ac-
tin and muscle specific actin varies in pattern. 
Desmin and focal cytokeratin immunoreactivity 
is identified in some cases. Myogenin, myoglobin, 
and S100 protein are negative [4, 12].
ALK expression may be negative by IHC; 
rearrangement for ALK locus by fluorescence in 
situ hybridization (FISH) may be required [39]
or newer IHC methods may have to be adopted 
[70]. Another difference between IPTs and IMTs 
is that on the basis of IHC and FISH characteri-
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A
B
C
Figure 2A–C. Computed tomography of the chest showing a mass in 
the right lower lobe with interspersed calcification
stics, IMTs have not been found to always be IgG4 
related [46]. As seen later, this fact may explain 
the response to steroids.
Prior to surgery, it is recommended to have 
liver function testing, pulmonary function testing 
and staging CT scans of the chest and upper 
abdomen. This helps to evaluate for concurrent 
IPTs/IMTs in other parts of the body [5]. Since 
morphological features do not predict biologic 
behavior, and the ploidy of the tumor needs to 
be determined [13]. One study reported serum 
Figure 3. Low magnification image showing extension of the tumor 
extending to the visceral pleura indicated by the black arrows
hyaluronan as a surrogate marker that correlated 
with changes in the IMT [14]. This needs further 
investigation.
Treatment
Surgery is considered the mainstay of treat-
ment. If complete resection is not possible, due to 
anatomic location or co-morbidities, then medical 
therapy in conjunction with radiation therapy 
could be considered.
Surgery
Complete surgical resection, when possible, 
is the best method for diagnosis and treatment 
[56, 61] (Fig. 4A, B). Lobectomy and pneumonec-
tomy should be performed if required for com-
plete cure. A recurrence rate of 8% was reported 
with a primarily surgical approach. However, it is 
unclear if the recurrence was local or distant [9].
Bronchoscopy and endobronchial 
resection
Rigid bronchoscopy and endobroncial re-
section (by surgical excision or laser) has been 
successful for IMTs confined to the trachea and 
smaller airways [71–74]. In some cases, this has 
been combined with use of steroids, with mixed 
results [75]. These patients should also be fol-
lowed closely and may require more extensive 
surgery if persistence of the lesion is seen [76].
Chemotherapy
Chemotherapy is useful in cases of multifocal, 
invasive lesions or in cases of local recurrence [77]. 
Carboplatin and Paclitaxel have been reported to be 
useful in some cases [78], but this response does 
not appear to be generalizable to all cases [79].
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Figure 4A, B. Histopathology of the tumor demonstrating spindle cells
A
B
Figure 5. Black arrows represent myofibroblastic cells: spindle cells 
with long cytoplasmic processes which are characteristic in IMT. 
White arrows pointing to plasma cells with characteristic perinuclear 
cytoplasm which are often seen in IMT
Figure 6. Arrows represent infiltrative inflammatory cells around 
a bronchiole that shows mucus plugging with inflammatory cells
Steroids
The use of steroids for IMTs is controversial. 
They were initially recommended to reduce 
surrounding inflammation, particularly in CNS 
IMTs [9]. IMT response to steroid therapy [68, 80] 
and steroids along with antibiotics [10], has 
been well-documented. One case of recurrent 
IPT, 11 years after steroid therapy, responded 
to repeat steroid therapy [25]. Some believe 
that the cases of IPTs/IMTs that responded to 
steroids could be based on the fact that they 
are IgG4-related, and this needs to be confir-
med with histopathology [81]. However, other 
studies have reported worsening of IMT with 
steroids [82, 83]. Moon et al. [83] reported ag-
gravation of pulmonary and bone metastases, as 
evident by radiologic worsening on bone scan 
and CT scan, as well as increased fibroblastic 
cell proliferation in cultures, in the presence 
of dexamethasone. However, we need larger 
studies to make determination of the efficacy 
of steroids for IMTs.
Non-steroidal anti-inflammatory drugs 
(NSAIDs)
NSAIDs like Celecoxib have been used for 
some cases of histologically-proven IMT that are 
negative for ALK and ROS-1 mutations [22, 84].
This was based on the hypothesis that NSAIDs 
inhibit cyclo-oxygenase-2 (COX-2) enzyme and 
vascular endothelial growth factor (VEGF) signa-
ling, thus interfering with angiogenesis. It was 
also observed that the level of ALK positivity in 
these cases did not correlate with the intensity 
of COX-2 or VEGF staining [85].
ALK RTK inhibitors and ROS-1 TK 
inhibitors
ALK RTK inhibitors (Crizotinib, Alectinib 
and Ceritinib) have been noted to be effective for 
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Figure 7. ALK and desmin staining of histopathologic sample
Figure 8. Gross pathology sample of a surgically removed IMT from 
a young adult
extra-pulmonary [86–88] and pulmonary IMTs 
[15]. They may be effective agents for patients with 
advanced or potentially unresectable ALK-rearran-
ged IMTs, regardless of the location of the primary 
lesion [15]. Crizotinib has also proven to be effecti-
ve in IMTs harboring ROS1 kinase fusions [21, 89].
Radiation
Radiation treatment has been shown to be of 
some benefit in pulmonary IMT [90, 91]. Failures 
of radiation therapy have, however, been reported 
suggesting that surgical excision should be prima-
ry therapy [81]. Radiation is typically reserved for 
palliation, to alleviate the mass effect of the IMT, 
or in conjunction with chemotherapy for cure in 
patients who are not amenable to resection [9]. As 
with chemotherapy, there is currently no evidence 
to support routine use of radiotherapy in patients 
who have complete resection.
Prognosis
Pulmonary IMT, if left untreated has shown 
an approximately 8% rate of growth on follow-up 
studies. In some cases of pulmonary IMT, sponta-
neous resolution has also been observed [92–94]. 
Prognosis is excellent after radical surgical exci-
sion, with 5-year survival rates greater than 91% 
[5, 95–97]. Patients who underwent complete 
resection showed better survival rates [12]. One 
study reported a 60% recurrence rate in those 
receiving incomplete resection [5]. Interestingly, 
IPTs confined to the lung recurred less frequently 
than extra-pulmonary IPTs; but, if the IPT spread 
outside the lung, it recurred more frequently than 
extra-pulmonary IPTs that had spread to different 
organs [98].
A combination of cellular atypia, ganglion-li-
ke cells, TP53 expression, and aneuploidy may 
help to identify IMT with a more aggressive poten-
tial [4]. ALK-positive IMT is associated with better 
prognosis than ALK-negative IMT, as ALK-negative 
is associated with higher rate of metastasis and re-
sistance to therapy [69]. Pulmonary IMT patients 
should have long-term follow up, due to the risk 
of recurrence and sarcomatous transformation 
[99]. Sarcomatous transformation has also been 
noted in extrapulmonary tumors [100].
Conclusion
Inflammatory myofibroblastic tumors (IMT) 
of the lung are a distinctive lesion composed of 
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myofibroblastic spindle cells accompanied by an 
inflammatory infiltrate of plasma cells, lympho-
cytes, and eosinophils. IMTs may follow a benign 
course, be locally invasive or metastasize. Patients 
may be asymptomatic, or present with cough, he-
moptysis, dyspnea, pleuritic pain, constitutional 
symptoms or pneumonia. Diagnosis is predomi-
nantly made using various imaging modalities 
and with histological confirmation. Genetic te-
sting should also be conducted to assess for the 
possibility or targeted adjuvant therapies. Primary 
treatment of choice is surgical resection as well 
as chemotherapy. Though rare, IMT should be on 
the differential in patients who clinically present 
with signs and symptoms of lung mass.
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